Wikipedia -WSS

Wikipedia

author：explore 2025-09-29 16:36:22 - browse：9

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

leisure time

WSS

Group opposing PBM reform sets lobbying record

AI can’t replace a physician’s gut feeling

Canadians with cystic fibrosis outlive Americans by a decade

A letter from the executive editor: The 2023 STATUS List

Drug cartel violence flares in western Mexico after vigilante leader's killing

STAT wants to know your pick for a great summer read or listen

hotspot

Wikipedia

focus

After affirmative action ruling, medical educators look to 'holistic review'

What affirmative action's end means to a medical student

Dobbs anniversary: the lost opportunity of abortion as health care

AstraZeneca lung cancer study comes in below expectations

In Memoriam: Notable people who died in 2023

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Virtual Event: The State of Biosimilars: What to Watch

Trump demands the U.S. pay no more for drugs than other countries … again

As digital health tech proliferates, a new institute aims to cut through hype

focus

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Security flaws in third

STAT wants to know your pick for a great summer read or listen

As digital health tech proliferates, a new institute aims to cut through hype

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Hubble vs. James Webb telescope images: See the difference

leisure time

explore

knowledge

focus